EGFR and posterior cortical atrophy: While a few trials showed moderate results in a subpopulation of PCa patients (e.g. erlotinib had moderate single-agent activity in chemotherapy-naïve CRPC (26), while cetuximab had some activity in those overexpressing EGFR and showing consistent expression of the tumor suppressor PTEN (17)), the majority of these trials failed to demonstrate efficacy.